Reported by Wu Liang-yi from Taipei

The Ministry of Health and Welfare (MOHW) announced last month that the eligibility criteria for the NHIA-reimbursed HCV new oral therapy will be loosened starting next year. Despite the effectiveness of the new oral drug, nearly 3% of HCV patients remains uncured after receiving a treatment regimen. In light of this, the MOHW has allocated NT$9.8 million to study the causes of treatment failure in the new HCV therapy.

【2018-12-16/Liberty Times】